Alicia Morgans, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Lantheus
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Myriad
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Progenics
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Advanced Accelerator Applications
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Sanofi
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Genetech
    Date added:
    Date updated:
    09/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Genetech
    Date added:
    Date updated:
    09/28/2023

Pages

Return to The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2022)